RT Journal Article
SR Electronic
T1 Exploring the use of synthetic placebo populations in ALS randomized clinical trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.09.22283281
DO 10.1101/2022.12.09.22283281
A1 Bowles, Harry
A1 Opie-Martin, Sarah
A1 Shojaie, Ali
A1 Libonati, Laura
A1 Iacoangeli, Alfredo
A1 Al Khleifat, Ahmad
A1 Al-Chalabi, Ammar
YR 2022
UL http://medrxiv.org/content/early/2022/12/13/2022.12.09.22283281.abstract
AB Objectives The use of synthetic data to supplement clinical trial placebo groups or for trial planning is rapidly gaining interest. However, there is not yet an established framework for generating synthetic data for these purposes. In this work we test two approaches to generating synthetic placebo arms for ALS trials with survival being the primary outcome variable.Methods For the first approach, we extracted sample subsets from the UK MND register (n = 308) using an evolutionary algorithm such that the subset baseline variables matched a target trials group, either people enrolled in LiCALS (n = 106) or people included in the PRO-ACT database (n = 171). We also applied trial specific exclusion criteria where possible or alternatively we applied a custom ‘time filter’. For the second approach, survival was predicted for LiCALS participants using the ENCALS model. Survival probabilities from each method were compared to real placebo participants using Kaplan-Meier analysis and the log rank test.Results We found that the synthetic placebo groups derived from the MND register matched the target trials outcomes very well. The ENCALS model produces synthetic placebo groups that are significantly different to the real placebo groups. However, when participants are censored at 6 month intervals, the ENCALS synthetic group matches the target group very well between 24 and 48 months, indicating a possible timeframe that this method could be utilised.Conclusion Both the register based approach and the ENCALS prognostic model generated synthetic placebo groups that matched placebo groups from historical trials. These methods need to be validated in prospective trials.Competing Interest StatementAAC is a consultant for Mitsubishi-Tanabe Pharma, GSK, and Chronos Therapeutics, and chief investigator for clinical trials for Cytokinetics and OrionPharma.; AAC serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Denali Pharma, Cytokinetics, Lilly, and Amylyx and has received a reeseach grant from Biogen.Funding StatementAAK is funded by The Motor Neurone Disease Association (MNDA), NIHR Maudsley Biomedical Research Centre and ALS Association Milton Safenowitz Research Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon request to the authors